News Focus
News Focus
Followers 843
Posts 122827
Boards Moderated 10
Alias Born 09/05/2002

Re: alertmeipp post# 3215

Tuesday, 09/24/2024 8:07:26 PM

Tuesday, September 24, 2024 8:07:26 PM

Post# of 6021
Re: Paxlovid settlement estimate

Let's estimate what ENTA would be due from PFE if ENTA prevailed in a trial. Including PFE's guidance for 2024, PFE will have sold about $12B of Paxlovid in the US market from product inception (Dec 2021) to 12/31/24. Let's apply a 3% royalty rate, which is pretty conservative for a patent-infringement case. Then the cumulative royalties due to ENTA would be (0.03)($12B) = $360M, plus interest.

(If the court found PFE to be guilty of willfull infringement, it could award ENTA treble damages, or about $1B plus interest. However, few patent-infringement suits result in treble damages, so this outcome is a longshot.)

If a win at trial would result in an award to ENTA of $360M plus interest, a settlement of $150M to ENTA (the estimate you cited from a sell-side analyst) seems like a lower bound. A settlement of $200-250M is more likely, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News